How can government regulations in developing countries make or break a clinical trial?

Success in getting prescription and OTC drugs on the market depends a lot on how well they work in a clinical trial. And as we see more and more CROs pop up all over the world, more clinical trial opportunities have arisen, and that is good. But as the University of Oxford's Trudie Lang and Sisira Siribaddana report in their study titled "Clinical Trials Have Gone Global: Is This a Good Thing?" government regulations for clinical trials in developing nations can put a damper in how they are organized and administered. An abstract of the study is available to read on PLoS Medicine.

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.